ImmunoPrecise Antibodies (IPA) reported strong financial results for its full fiscal year 2025, including record revenue for the fourth quarter and a new high in adjusted EBITDA for the same period. The company highlighted its performance in a detailed release, showing continued growth and operational efficiency. Fourth quarter revenue reached a new milestone, reflecting increased demand for its antibody products and services. Adjusted EBITDA also hit a record level, indicating improved profitability and effective cost management. These results underscore IPA's progress in its core business areas and its ability to deliver consistent financial performance. The company’s leadership emphasized the significance of these achievements as part of its broader strategy to expand its market presence and enhance shareholder value. Despite the positive outcomes, IPA remains focused on navigating the challenges of the biotechnology sector, including evolving regulatory landscapes and competitive pressures. The strong fiscal year performance positions the company to continue its growth trajectory in the coming years.

A federal judge in California ruled that training AI models on legally purchased physical books without author permission is fair use, marking a significant milestone for the AI industry. The decision, in the case against Anthropic, allows the company to use its AI training data, but does not extend to pirated internet books, which will face a separate trial. The ruling highlights the evolving legal landscape around AI and copyright, emphasizing the transformative nature of AI models, which do not replicate specific works but create new content. The case, brought by authors Andrea Bartz, Charles Graeber, and Kirk Wallace Johnson, accused Anthropic of using their works without consent, but the judge noted that such practices are akin to students learning from books to create original work. Despite this win, the court will assess the company's use of pirated books, which could lead to damages. The decision could influence future AI copyright cases, though it is not binding on other courts. ImmunoPrecise Antibodies Ltd. (IPA), a bio-native AI company in drug discovery, reported strong financial results for FY 2025, with record fourth-quarter revenues, improved gross margins, and a significant adjustment in EBITDA, showing a loss of just $316,000. The company's LENSai platform demonstrated success in in silico epitope mapping, identifying a conserved dengue virus epitope, a step toward a universal vaccine. IPA's AI-designed GLP-1 peptides matched semaglutide in studies, validating its HYFT-powered platform. The company entered a $8–10 million partnership with a biotech firm focused on oncology therapeutics and realigned R&D to launch an AI-powered therapeutic pipeline. IPA's subsidiary signed a material transfer agreement with BioNTech, and successfully engineered antibodies for a challenging tumor target. The company also appointed Jon Lieber to its board and Jeff Fried to its advisory board, enhancing its leadership and AI capabilities. IPA regained compliance with Nasdaq listing standards, reflecting investor confidence. In the fourth quarter of 2025, IPA reported $7.0 million in revenue, an 8% increase from the same period in 2024. Gross profit rose to $4.5 million, with a 64% gross margin, up from 48% in 2024. R&D expenses decreased due to reallocation to cost of sales, while sales and marketing expenses increased. General and administrative costs dropped, contributing to an improved operating loss and net loss. Full-year revenue remained steady at $24.5 million, with a 12.4% increase in gross profit and a 600 basis point rise in gross margin. R&D and sales expenses increased, while general and administrative costs decreased, leading to an improved operating loss and net loss. IPA ended FY2025 with $10.8 million in cash and equivalents. IPA’s CEO, Dr. Jennifer Bath, highlighted the company’s progress toward profitability and innovation, noting the BioStrand segment's 180% growth. The company plans to refocus on AI-based product development, streamline operations, and complete the divestiture of its Dutch subsidiary. The company also cautioned about risks and uncertainties, including market adoption, technology commercialization, and financial conditions. Forward-looking statements in the press release include expectations for future growth, strategic partnerships, and profitability. IPA uses non-IFRS measures like adjusted EBITDA to evaluate performance. The company’s financial statements, including cash flows and balance sheets, are available for review. Investors are encouraged to read periodic reports and consider risk factors before making decisions. The company’s focus on AI-driven antibody discovery and therapeutic design underscores its commitment to innovation and commercial impact.